Spread the love

A study from the Abramson Family Cancer Research Institute, Philadelphia, USA; and Howard Hughes Medical Institute, Philadelphia, USA shows that “Fructose-1,6-bisphosphatase opposes renal carcinoma progression.”

This study was published in the September issue of 2014 Nature by Prof. M. Celeste Simon, Li B0 [I.F >42] and others from the Abramson Family Cancer Research Institute and  Howard Hughes Medical Institute, Philadelphia, USA.

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMDreports here that: Tumor suppressor ARF increases the expression of Fructose-1,6-bisphosphatase (FBP1) via up regulation of its target gene.  This study may suggest that ARF, by up regulating its target gene, it may induce FBP1. Thereby, it may inhibit (1) the expression of hypoxia-inducible factor (HIF-1); (2) glycolysis; and (3) the progression of renal cell carcinoma. Together, this study suggests that pharmacological formulations encompassing “ARF or its activators can be used in the treatment of  renal cell carcinoma.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, L., Tumor suppressor ARF increases the expression of Fructose-1,6-bisphosphatase (FBP1) via up regulation of its target gene, 18/September/2014, 08.10 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation


Spread the love